ReviewEuropean respiratory review : an official journal of the European Respiratory Society2025
Biologics in severe asthma: a state-of-the-art review.
Review in European respiratory review : an official journal of the European Respiratory Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- The Clinical and Economic Impact of Biologic Agents in Asthma Management: a Systematic Review.Lung · 2026Pooled it
- Patterns and Clinical Efficacy of Biologics Switching in Patients With Severe Asthma: A Systematic Review and Meta-Analysis.Allergy · 2026Pooled it
- Metabolic dysfunction, antidiabetic drugs, and asthma: bibliometric evidence, emerging trends, and translational frontiers from 2006 to 2025.Frontiers in endocrinology · 2026Pooled it
- Efficacy and Safety of Biologics Targeting Type 2 Inflammation in COPD: A Systematic Review and Network Meta-Analysis.International journal of chronic obstructive pulmonary disease · 2025Pooled it
- The efficacy and safety of biologics for patients with severe asthma: an umbrella review of systematic reviews and meta-analyses.Frontiers in medicine · 2025Pooled it
- Switching to twice-yearly depemokimab from mepolizumab/benralizumab in severe asthma: a multicenter, randomized, double-blind, phase 3A clinical trial (NIMBLE).American journal of respiratory and critical care medicine · 2026Trial
- Effect of Digital Self-Monitoring on Patient Engagement and Clinical Outcomes in Severe Asthma: A Randomized Controlled Pilot Study.Medicina (Kaunas, Lithuania) · 2026Trial
- Depemokimab: A twice yearly anti-IL 5 biologic for chronic rhinosinusitis with nasal polyps (CRSwNP) - A narrative review.Human vaccines & immunotherapeutics · 2026Review
- Different Inflammatory Phenotypes and Immune Endotypes Drive Disease Heterogeneity in Asthma and COPD.Clinical reviews in allergy & immunology · 2026Review
- Asthma and Sinonasal Diseases: Shared Clinical Comorbidities, Inflammatory Pathways and Management Strategies.Medical sciences (Basel, Switzerland) · 2026Review
- Therapeutic Switching of Biological Drugs in Paediatric Severe Asthma: Experience of a Referral Centre.Biomedicines · 2026Article
- Bridging the Knowledge Gap: Transforming COPD Management Through Lessons from Asthma.Pulmonary therapy · 2026Review
- Longer Asthma Duration Is Associated With Elevated Non-T2 Sputum Biomarkers and Reduced T2 Inflammation in Severe Asthma.Allergy · 2026Observational
- Prevalence and cost implications of broadening asthma biologic eligibility criteria.The World Allergy Organization journal · 2026Article
- Post-genome-wide association study variant-to-function challenges in asthma research.The Journal of allergy and clinical immunology · 2026Review
- Clinical diagnosis and treatment of eosinophilic asthma by respiratory physicians in China: a cross-sectional survey.Journal of thoracic disease · 2026Article
- Clinical Remission Trajectories Beyond 12 Months in Severe Asthma Patients Continuing a Single Biologic: A Real-World Single SANI Center Cohort.Medical sciences (Basel, Switzerland) · 2026Article
- Real-World Effectiveness of Dupilumab in Severe Uncontrolled Asthma: Clinical Remission on Treatment, Predictors of Complete Response and Impact on Type-2 Comorbidities.Journal of clinical medicine · 2026Article
- Mechanisms and therapeutic strategies of asthma: from bench to bedside.Signal transduction and targeted therapy · 2026Review
- Real-world characterisation of severe asthma in Greece: results from the Greek Severe Asthma Registry.ERJ open research · 2026Article
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asthma is considered severe if it remains uncontrolled despite optimal conventional therapy, characterised by poor symptom control, frequent exacerbations and increased exposure to systemic corticosteroids. This has a significant impact on morbidity, mortality and healthcare resource utilisation. Recent advances in the understanding of asthma heterogeneity and immunopathogenesis have helped delineate precise disease pathways. The discovery of these pivotal pathways has led to the development of highly effective biologic therapies. Currently available asthma biologics target immunoglobulin E, interleukin (IL)-5/IL-5Rα, IL-4Rα and thymic stromal lymphopoietin. Identification of specific asthma phenotypes, utilising easily measurable biomarkers, has paved the way towards personalised and precision asthma management. Biologic therapies play a significant role in reducing exacerbations, hospitalisations and the need for maintenance systemic steroids, while also improving the quality of life in patients with severe asthma. The evidence for their clinical efficacy comes from randomised controlled trials (RCTs), extension studies, metanalyses and real-world data. This review synthesises findings from early, pivotal RCTs and subsequent studies following the approval of biologics for severe asthma. The safety and efficacy data from these studies, completed in a variety of settings, provide practical perspectives on their application and enhance their generalisability.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.